DEF: Autonomix Medical Seeks Reverse Split, Boosts Equity Plan

Autonomix Medical, Inc. will hold its Annual Meeting to vote on a reverse stock split, an expanded equity incentive plan, and a $15 million capital raise agreement with Lincoln Park Capital.

Summary

• Stockholders will vote on five key proposals at the Annual Meeting on October 30, 2025, including the election of five directors and the ratification of Forvis Mazars, LLP as the independent auditor for fiscal year 2026.
• A proposal to amend the company's certificate of incorporation to grant the Board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-25 is on the agenda, primarily to maintain Nasdaq listing compliance.
• Approval is sought for an amendment to the 2023 Equity Incentive Plan, increasing authorized shares from 371,968 to 2,271,968, to attract and retain talent and conserve cash for clinical trials.
• Stockholders will also vote on approving the issuance of more than 20% of outstanding common stock to Lincoln Park Capital Fund, LLC under a purchase agreement for up to $15.0 million, as required by Nasdaq Listing Rule 5635(d).
• The company issued 261,932 commitment shares to Lincoln Park Capital Fund, LLC as consideration for the purchase agreement.
• Executive compensation for fiscal year 2025 included Brad Hauser (CEO) with a total of $1,662,561, Lori Bisson (Executive Vice Chairman) with $659,098, Dr. Robert Schwartz (Chief Medical Officer) with $381,111, Landy Toth (Chief Technology Officer) with $313,158, Trent Smith (CFO) with $618,131, and Walter Klemp (Executive Chairman) with $325,658.
• Several executives, including Dr. Schwartz, Mr. Toth, and Mr. Klemp, took voluntary pay reductions for fiscal year 2026, resulting in annual salaries of $50,000 for each.

Sentiment

Score: 4

Explanation: The filing presents a mixed outlook. While the company is taking proactive steps to address Nasdaq listing compliance and secure capital through the Lincoln Park agreement, the necessity of a reverse stock split and the dilutive nature of the capital raise indicate significant financial challenges and a low current valuation. The voluntary pay reductions for some executives also suggest cost-cutting measures. The overall sentiment leans negative due to the underlying issues prompting these actions, despite the forward-looking strategic goals.

Positives

• The proposed reverse stock split aims to maintain the company's listing on the Nasdaq Capital Market, which is crucial for liquidity and investor access.
• A higher stock price post-split could attract institutional investors and investment funds, potentially improving trading liquidity.
• The amended 2023 Equity Incentive Plan, with an increased share pool, is designed to attract and retain key employees, directors, and consultants, aligning their interests with stockholder value creation.
• The purchase agreement with Lincoln Park Capital Fund, LLC provides a potential source of up to $15.0 million in capital for working capital and general corporate purposes.
• The company is actively pursuing strategic partnerships, progress on pivotal trials, and completion of clinical proof of concept trials, indicating ongoing development.

Negatives

• The necessity of a reverse stock split indicates the company's common stock price is near or below the Nasdaq minimum listing requirement of $1.00 per share, signaling underlying market concerns.
• There is no assurance that a reverse stock split will result in a sustained higher stock price or improved trading liquidity, and the market capitalization could decline.
• The issuance of shares under the Lincoln Park Capital Fund, LLC agreement and the expanded equity incentive plan will result in significant dilution for existing stockholders.
• Some executive officers (Dr. Schwartz, Mr. Toth, Mr. Klemp) took voluntary pay reductions for fiscal year 2026, which could be interpreted as a measure to conserve cash or reflect financial pressures.
• One Form 4 by David Robins, a director, reporting one transaction was filed late on July 26, 2024, indicating a minor compliance lapse.

Risks

• The reverse stock split may not achieve the desired effect of increasing the stock price or attracting institutional investors, and the stock price could decline further.
• Reduced liquidity of common stock could occur after a reverse stock split due to fewer outstanding shares, potentially making it harder for investors to buy or sell shares.
• Stockholders may end up with 'odd lots' (less than 100 shares) after a reverse stock split, which can be more difficult and costly to sell.
• The increase in authorized but unissued shares post-reverse split could have an anti-takeover effect and facilitate future dilutive issuances without further stockholder approval.
• The issuance of shares to Lincoln Park Capital Fund, LLC will dilute existing stockholders' ownership and voting power, and could negatively impact the stock price.
• Failure to obtain stockholder approval for the Lincoln Park Capital Fund, LLC agreement would limit the company's ability to access the full $15.0 million in capital.
• The company's ability to achieve its corporate goals, including securing strategic partnerships, progressing pivotal trials, and completing financings, is subject to various market and operational risks.

Future Outlook

The company plans to continue its focus on securing strategic partnerships, progressing its pivotal trial, completing financings, achieving design lock for its catheter, and completing the second phase of its clinical proof of concept trial. The Board intends to effect a reverse stock split only if necessary to maintain Nasdaq listing and believes it may improve the stock's attractiveness to institutional investors. Equity grants will continue to be a significant part of employee compensation to conserve cash for clinical trials.

Management Comments

• Walter V. Klemp, Executive Chairman, cordially invited stockholders to attend the Annual Meeting, emphasizing the importance of voting in advance if unable to attend to ensure a quorum.

Industry Context

Autonomix Medical operates in the medical device industry, with executive experience noted in aesthetics and interventional cardiology. The company's strategy to use equity compensation and conserve cash for clinical trials is a common practice in the capital-intensive medical device development sector. The need for a reverse stock split highlights challenges faced by smaller companies in maintaining public market visibility and meeting listing standards, a common issue in the highly competitive and regulated medical technology space.

Comparison to Industry Standards

• The company's approach to using equity as a significant part of employee compensation aligns with industry standards, particularly for medical device companies that need to conserve cash for R&D and clinical trials. Many competitors in the industry utilize similar equity incentive programs.
• The target bonus percentages for executives (e.g., 60% for CEO, 50% for Executive Vice Chair, 40% for CFO) are within a reasonable range for executive incentive plans in the medical device sector, aiming to motivate performance against corporate goals.
• The company's pursuit of strategic partnerships and clinical trial progress is standard for medical device companies aiming for commercialization, comparable to development stages seen in companies like Soliton, Inc. (acquired by AbbVie) where some of Autonomix's management previously worked.

Management Changes

Corporate Governance

Related Party Transactions

• In December 2021, the company granted a license to its technology for use in cardiology to a company affiliated with certain early investors. This license was terminated in July 2023 in exchange for a warrant to purchase 80,000 shares of common stock at an exercise price of $0.02 per share. Director David Robins holds a 19.5% interest in the recipient company.
• In September 2023, members of the company's management, Board of Directors, and an immediate family member of management collectively purchased $500,000 in principal amount of convertible notes in a private placement.

Stakeholder Impact

• Shareholders: Will vote on critical proposals, face potential dilution from capital raise and equity plan, and may experience changes in stock price and liquidity due to the reverse stock split.
• Employees: Benefit from the expanded equity incentive plan, which aims to attract and retain talent, but some executives have taken voluntary pay reductions.
• Customers: No direct impact mentioned, but continued development and clinical trials aim to bring new medical devices to market.
• Creditors: The capital raise from Lincoln Park Capital Fund, LLC could improve the company's financial position, potentially benefiting creditors.
• Lincoln Park Capital Fund, LLC: Becomes a significant investor with the right to purchase up to $15.0 million in common stock, subject to certain conditions and approvals.

Next Steps

• Hold the Annual Meeting of Stockholders on October 30, 2025, to vote on the proposed resolutions.
• If approved, the Board of Directors will determine the specific ratio and timing for the reverse stock split within one year of the Annual Meeting.
• If approved, the company will proceed with the amended 2023 Equity Incentive Plan, increasing the number of shares authorized for issuance.
• If approved, the company will be able to issue more than 20% of its common stock to Lincoln Park Capital Fund, LLC under the purchase agreement, providing access to up to $15.0 million in capital.
• Continue efforts in securing strategic partnerships, progressing the pivotal trial, and completing the second phase of the clinical proof of concept trial.

Key Dates

Recommendation

The company is at a critical juncture, addressing its Nasdaq listing compliance through a proposed reverse stock split and securing a significant capital commitment from Lincoln Park Capital. While these actions are necessary to ensure continued operations and market access, the need for a reverse split signals underlying weakness in the stock price, and the capital raise will be dilutive. The expanded equity incentive plan is a positive for talent retention, but the overall picture suggests a company facing significant challenges. A 'hold' recommendation is appropriate as investors should monitor the execution of these strategic initiatives and the company's progress in clinical trials before making further investment decisions. The potential for a higher stock price post-split is offset by the risk of further decline and dilution.

Keywords

Autonomix Medical, DEF 14A, Proxy Statement, Annual Meeting, Reverse Stock Split, Nasdaq Listing, Equity Incentive Plan, Lincoln Park Capital, Capital Raise, Stock Dilution, Corporate Governance, Executive Compensation, Medical Device